Skip to main content

Can you take Gevratonic with Omadacycline?

1 drug interaction and 2 additional warnings found for the following 2 drugs:

Add/remove drugs

Drug interactions

Moderate drug interactions

Moderate:

multivitamins with minerals omadacycline

Applies to: Gevratonic (multivitamin with minerals) and omadacycline

In general, multivitamins with minerals and omadacycline should not be taken orally at the same time. Products that contain aluminum, calcium, iron, magnesium, zinc and/or other minerals may interfere with the absorption of omadacycline into the bloodstream and reduce its effectiveness in treating your infection. If possible, it may be best to avoid taking multivitamins with minerals while you are being treated with omadacycline. Otherwise, you should separate their dosing times by as much as possible, usually at least 2 to 4 hours. Talk to your healthcare provider if you are unsure whether your medications contain something that could potentially interact or if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food/lifestyle interactions

Moderate food/lifestyle interactions

Moderate:

omadacycline Food/Lifestyle

Applies to: omadacycline

Do not take iron supplements, multivitamins, calcium supplements, or antacids within 4 hours before or after taking omadacycline. These products can make omadacycline less effective in treating your infection. Omadacycline should be taken at least 2 hours before (4 hours for dairy products) or 4 hours after meals. Dairy products can make it harder for your body to absorb the medication.

Disease interactions

1 potential interaction Applies to: 1 condition, including Noninfectious Colitis.

Noninfectious Colitis

Major:

omadacycline

Omadacycline has a major potential interaction with Noninfectious Colitis.

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

More resources

Gevratonic

A total of 112 drugs are known to interact with Gevratonic.

omadacycline

A total of 162 drugs are known to interact with omadacycline.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.